[CGEN] Compugen Ltd.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 5.25 Change: 0.1 (1.94%)
Ext. hours: Change: 0 (0%)

chart CGEN

Refresh chart

Strongest Trends Summary For CGEN

CGEN is in the medium-term up 21% in 3 months. In the long-term down -67% below S&P in 8 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Compugen Ltd., a therapeutic product discovery company, is engaged in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates primarily in the United States, Europe, and Israel. It focuses on the therapeutic proteins and monoclonal antibodies to address unmet needs in the fields of immunology and oncology. The company?s therapeutic proteins pipeline includes CGEN-15001, CGEN-15021, CGEN-15091, CGEN-15031, and CGEN-15051 fusion protein candidates for the treatment of autoimmune diseases and inflammatory conditions, such as multiple sclerosis and rheumatoid arthritis. Its monoclonal antibody therapy product candidates include CGEN-15001T, CGEN-15022, and CGEN-15049; and CGEN-671, a novel antibody-drug conjugate. Compugen Ltd. was incorporated in 1993 and is headquartered in Tel Aviv, Israel.

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities72.13 M Cash From Investing Activities-64.09 M Cash From Operating Activities-11.15 M Gross Profit130 K
Net Profit-6.14 M Operating Profit-6.32 M Total Assets108.48 M Total Current Assets68.55 M
Total Current Liabilities5.24 M Total Debt Total Liabilities7.52 M Total Revenue510 K
Technical Data
High 52 week4.19 Low 52 week2.78 Last close3.55 Last change-0.56%
RSI57.34 Average true range0.23 Beta0.72 Volume73.51 K
Simple moving average 20 days6.41% Simple moving average 50 days3.08% Simple moving average 200 days2.82%
Performance Data
Performance Week11.64% Performance Month-0.84% Performance Quart-0.84% Performance Half4.72%
Performance Year5.97% Performance Year-to-date16.78% Volatility daily3.88% Volatility weekly8.66%
Volatility monthly17.76% Volatility yearly61.52% Relative Volume296.09% Average Volume211.24 K
New High New Low

News

2019-11-11 07:00:00 | Compugen Reports Third Quarter 2019 Results

2019-11-06 08:30:00 | Compugen Expands Patent Portfolio for COM902 with New Composition of Matter and Use Patent in Europe

2019-11-05 08:06:00 | Compugen Presents Preclinical Data for COM902 Anti-TIGIT Program at SITC 2019

2019-11-05 08:05:00 | Compugen Presents Initial Clinical Data from Ongoing Phase 1 Trial of COM701 in Patients with Advanced Solid Tumors at SITC 2019

2019-11-04 07:00:00 | Compugen Announces FDA Clearance of IND Application for COM902

2019-10-28 07:00:00 | Compugen to Release Third Quarter 2019 Results on Monday, November 11, 2019

2019-10-12 09:28:32 | We Think Compugen NASDAQ:CGEN Can Afford To Drive Business Growth

2019-10-10 09:00:01 | Compugen CGEN Upgraded to Buy: Here's What You Should Know

2019-10-02 07:00:00 | Compugen to Present Data from Ongoing COM701 Phase 1 Clinical Trial at SITC 2019

2019-09-19 07:00:00 | Compugen Presents Update on COM701 Phase 1 Study at 2019 IGCS

2019-08-28 12:52:59 | How Should Investors Feel About Compugen Ltd.'s NASDAQ:CGEN CEO Pay?

2019-08-22 12:01:04 | MyoKardia Begins Dosing in Phase I Study on Heart Candidate

2019-08-14 12:18:04 | Vaccinex VCNX Attains Full Enrollment in Lung Cancer Study

2019-08-13 11:53:03 | Mallinckrodt Enrolls First Patient in Liver Disease Study

2019-08-08 11:20:03 | AMAG Q2 Loss Widens, Sales Lag Estimates, 2019 Guidance Cut

2019-08-05 16:16:57 | Compugen Ltd. CGEN Q2 2019 Earnings Call Transcript

2019-08-05 07:00:00 | Compugen Reports Second Quarter 2019 Results

2019-07-22 07:00:00 | Compugen Second Quarter 2019 Conference Call Scheduled for Monday, August 5, 2019 at 8:30 AM ET

2019-07-16 07:00:00 | Compugen Expands Intellectual Property Portfolio for COM701 with New U.S. Patent Covering Combination Use with anti-PD-1 Antibody

2019-07-02 07:00:00 | Compugen Appoints Eran Perry to Its Board of Directors

2019-06-27 15:07:27 | How Many Compugen Ltd. NASDAQ:CGEN Shares Do Institutions Own?

2019-06-27 15:05:29 | Do Institutions Own Shares In Compugen Ltd. NASDAQ:CGEN?

2019-06-26 09:00:01 | Compugen CGEN Upgraded to Strong Buy: Here's What You Should Know

2019-06-12 09:14:21 | The Compugen NASDAQ:CGEN Share Price Is Down 63% So Some Shareholders Are Wishing They Sold

2019-06-03 07:00:00 | Compugen Presents Update on COM701 Phase 1 Trial at the 2019 ASCO Annual Meeting

2019-05-23 09:00:01 | Compugen CGEN Upgraded to Buy: Here's What You Should Know

2019-05-22 07:00:00 | Compugen to Present at the Jefferies 2019 Healthcare Conference

2019-05-20 18:08:55 | Stocks Close Lower on Monday

2019-05-20 16:00:59 | Compugen Ltd. CGEN Q1 2019 Earnings Call Transcript

2019-05-20 10:13:24 | Compugen: 1Q Earnings Snapshot

2019-05-20 07:05:00 | Compugen Reports First Quarter 2019 Results

2019-05-20 07:00:00 | Compugen Doses First Patient in COM701/Opdivo® Nivolumab Combination Arm of Phase 1 Study in Patients With Advanced Solid Tumors

2019-05-06 07:00:00 | Compugen First Quarter 2019 Conference Call Scheduled for Monday, May 20, 2019 at 8:30 AM ET

2019-04-18 09:00:01 | What Makes Compugen CGEN a New Strong Buy Stock

2019-04-03 07:00:00 | Compugen Presents Update on COM701 Phase 1 Trial at the 2019 AACR Annual Meeting

2019-03-26 08:40:00 | Chinese Regulatory Authority Approves IND Application of Oramed's Oral Insulin Capsules

2019-03-26 07:00:00 | Compugen Announces Purchase of Company Shares by its Board of Directors and Members of Management

2019-03-12 07:46:00 | Compugen Announces Issuance of Two U.S. Composition of Matter Patents for COM701, Its Lead Immuno-Oncology Product Candidate

2019-03-08 10:04:03 | Achillion ACHN Reports Narrower-Than-Expected Loss in Q4

2019-03-07 09:09:02 | Compugen CGEN Upgraded to Strong Buy: What Does It Mean for the Stock?

2019-03-07 09:06:02 | Merrimack MACK Incurs Narrower-Than-Expected Loss in Q4

2019-03-05 07:00:00 | Compugen to Present at the Cowen and Company 39th Annual Health Care Conference

2019-03-01 07:00:00 | Compugen Presents Update on COM701 Phase 1 Trial at ASCO-SITC Clinical Immuno-Oncology Symposium

2019-02-26 02:00:00 | Compugen Reports Fourth Quarter and Full Year 2018 Results and Announces Corporate Restructuring to Streamline Operations

2019-02-14 07:00:00 | Compugen Fourth Quarter and Full Year 2018 Conference Call Scheduled for Tuesday, February 26, 2019 at 8:30 AM ET

2019-01-22 07:00:00 | Compugen Announces Publication of Two Peer-Reviewed Papers Demonstrating the Role of PVRIG as a Novel Immune Checkpoint for Cancer Immunotherapy

2019-01-16 07:07:39 | How Much Of Compugen Ltd. NASDAQ:CGEN Do Institutions Own?

2019-01-14 07:00:00 | Compugen's Phase 1 Trial of COM701 Featured as a Trial-in-Progress at The ASCO-SITC Clinical Immuno-Oncology Symposium

2018-11-23 08:20:00 | New Research Coverage Highlights Vulcan Materials, Cimpress N.V, Asterias Biotherapeutics, ElectraMeccanica Vehicles, Compugen, and China HGS Real Estate — Consolidated Revenues, Company Growth, and Expectations for 2018

2018-11-13 07:00:00 | Compugen Announces Issuance of U.S. Patent for COM902, Its TIGIT Antibody Product Candidate for Cancer Immunotherapy